|
|
|
30.06.25 - 22:31
|
XFRA: Deletion of Instruments from Boerse Frankfurt - 30.06.2025 (XETRA)
|
|
|
The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2025
Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2025
ISIN Name
CA13758Y2015 CANICKEL MINING
DE0007775207 WESTAG AG INH ST O.N.
DE0007775231 WESTAG AG INH VZO O.N.
GB00BV9GHQ09 KINOVO PLC LS -,10
GB00BY9D0Y18 DIR.LINE.INS.LS-,10909090
JP3131430005 AEON MALL CO. LTD.
US04686J3095 ATHENE HOLDING PRF.SER.C
US05478C1053 AZEK CO. INC. CL.A
US69291A1007 PHX MINERALS A DL-,01666
US75915K3095 REGULUS THER.COMPAR DL001...
|
|
|
|
|
25.06.25 - 15:15
|
Novartis completes acquisition of Regulus Therapeutics (GlobeNewswire EN)
|
|
|
Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis....
|
|
|
25.06.25 - 14:31
|
Novartis kann Regulus-Übernahme abschliessen (Handelszeitung)
|
|
|
Novartis kann die Übernahme des US-Biotechunternehmen Regulus Therapeutics erfolgreich abschliessen. Wie der Konzern am Mittwoch mitteilte, wurden ihm zum Ende der nun abgelaufenen Angebotsfrist 74,49 Prozent der ausstehenden Anteile angeboten....
|
|
|
25.06.25 - 11:31
|
Novartis kann Regulus-Übernahme abschliessen (Handelszeitung)
|
|
|
Novartis kann die Übernahme des US-Biotechunternehmen Regulus Therapeutics erfolgreich abschliessen. Wie der Konzern am Mittwoch mitteilte, wurden ihm zum Ende der nun abgelaufenen Angebotsfrist 74,49 Prozent der ausstehenden Anteile angeboten....
|
|
|
25.06.25 - 08:45
|
XFRA: 7RG0: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
REGULUS THER.COMPAR DL001 7RG0 US75915K3095 BAW/UFN...
|
|
|
25.06.25 - 08:31
|
Novartis kann Regulus-Übernahme abschliessen (Handelszeitung)
|
|
|
Novartis kann die Übernahme des US-Biotechunternehmen Regulus Therapeutics erfolgreich abschliessen. Wie der Konzern am Mittwoch mitteilte, wurden ihm zum Ende der nun abgelaufenen Angebotsfrist 74,49 Prozent der ausstehenden Anteile angeboten....
|
|
|
|
|
|
|
25.06.25 - 07:03
|
Novartis announces expiration of Regulus Therapeutics tender offer (GlobeNewswire EN)
|
|
|
Basel, June 25, 2025 – Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc. (“Regulus”), in exchange for (i) $7.00 in cash per share, subject to any applicable withholding and without interest thereon, plus (ii) one contingent value right (each, a “CVR”) per Share, representing the right to receive one contingent payment of $7.00 in cash, subject to any applicable withholding and without interest thereon, upon the achievement of a regulatory milestone, expired at one minute past 11:59 p.m., New York City Time, on June 24, 2025 (the “Expiration Time”)....
|
|
|
|
|
|
|
23.06.25 - 07:03
|
Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer (GlobeNewswire EN)
|
|
|
Basel, June 23, 2025 – Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Novartis' previously announced tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc. (“Regulus”), in exchange for (i) $7.00 in cash per Share, subject to any applicable withholding and without interest thereon, plus (ii) one contingent value right (each, a “CVR”) per Share, representing the right to receive one contingent payment of $7.00 in cash, subject to any applicable withholding and without interest thereon, upon the achievement of a regulatory milestone. The expiration of the HSR Act waiting period occurred at 11:59 p.m., New York City Time, on June 20, 2025....
|
|
|
|
|
|
|
27.05.25 - 14:00
|
Novartis announces commencement of tender offer to acquire Regulus Therapeutics (GlobeNewswire EN)
|
|
|
Basel, May 27, 2025 - Novartis today announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc., a Delaware corporation (“Regulus”), in exchange for (i) $7.00 in cash per Share, subject to any applicable withholding and without interest thereon, plus (ii) one contingent value right (each, a “CVR”) per Share, representing the right to receive one contingent payment of $7.00 in cash, subject to any applicable withholding and without interest thereon, upon the achievement of a regulatory milestone. Such offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase, dated May 27, 2025, and the related Letter of Transmittal (together, the “Offer”) and pursuant to the terms of the previously announced Agreement and Plan of Merge...
|
|
|
09.05.25 - 12:45
|
April Recap: 15 Top Health Press Releases (PR Newswire)
|
|
|
A roundup of the most newsworthy healthcare press releases from PR Newswire, including Eli Lilly's GLP-1 medication study results and business updates from Crunch Fitness and Regulus Therapeutics. NEW YORK, May 9, 2025 /PRNewswire/ -- With thousands of press releases published each month,......
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
